Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

Benzinga Newsdesk www.benzinga.com Neutral 55.7%

Neg 0% Neu 55.7% Pos 0%

Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $7.